Obesity Surgery

, Volume 28, Issue 4, pp 907–915 | Cite as

Bariatric Embolization of the Left Gastric Arteries for the Treatment of Obesity: 9-Month Data in 5 Patients

  • Zhi-Bin Bai
  • Yong-Lin Qin
  • Gang Deng
  • Guo-Feng Zhao
  • Bin-Yan Zhong
  • Gao-Jun TengEmail author
Original Contributions



The purpose of this study is to investigate the safety and 9-month effectiveness of transcatheter left gastric artery embolization (LGAE) for treating patients with obesity.

Materials and Methods

The protocol of this study was approved by the Institutional Ethics Review Board. Five obese patients (3 men and 2 women) with mean weight of 102.0 ± 16.19 kg (range, 82.1–125.5 kg) and mean body mass index (BMI) of 38.1 kg/m2 ± 3.8 (range, 32.9–42.4 kg/m2) underwent LGAE with polyvinyl alcohol (PVA) particles in diameter of 500–710 μm. The primary endpoint was the safety by grading the adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE v4.0) within 30 days after LGAE. The secondary endpoints were measured with serum ghrelin and leptin levels, body weight, waist circumference, waist-to-height ratio, and abdominal fat quantity on MRI at the day immediately before LGAE and every 3 months after LGAE.


LGAE was successfully performed in all patients. A superficial linear ulceration below the cardia was seen in 1 patient 3 days after LGAE and healed within 30 days. No other serious AEs (grade III or above) occurred. Average body weight loss at 3, 6, and 9 months was 8.28 ± 7.3 kg (p = 0.074), 10.42 ± 8.21 kg (p = 0.047), and 12.9 ± 14.66 kg (p = 0.121), respectively. The level of serum ghrelin decreased by 40.83% (p = 0.009), 31.94% (p = 0.107), and 24.82% (p = 0.151) at 3, 6, and 9 months after LGAE, respectively. There was minimal reduction of leptin levels at 3 and 6 months following LGAE (decreased by 0.26%, p = 0.929, and 4.33%, p = 0.427, respectively), but it declined obviously 9 months after LGAE (decreased by 11.22%, p = 0.295).

Both waist circumference and waist-to-height ratio decreased after LGAE. MRI showed the area of subcutaneous adipose tissue decreased from the baseline of 400.90 ± 79.25 to 320.36 ± 68.06 cm2 (decreased by 20.09%, p = 0.006) at 3 months, to 328.31 ± 52.67 cm2 (decreased by 18.11%, p = 0.020) at 6 months, and to 286.40 ± 55.72 cm2 (decreased by 28.52%, p = 0.101) at 9 months after LGAE, respectively. But the decrease of abdominal fat loss at 9 months after LGAE was largely due to the reduction in visceral adipose tissue.


Our study with 9-month data in 5 patients indicates that bariatric embolization of the LGA is a safe and may be a promising strategy to suppress the production of ghrelin and results in weight loss and abdominal fat reduction.

Trial Registration (NCT02786108).


Bariatric embolization Left gastric artery Obesity Weight loss Ghrelin 



This study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), China; National Basic Research Program of China (973 Program # 2013CB733800, 2013733803), and National Natural Science Foundation of China (81230034, 81520108015).

Compliance with Ethical Standards

The protocol of this study was approved by our Institutional Ethics Review Board (IERB)

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Au N, Johnston DW. Too much of a good thing? Exploring the impact of wealth on weight. Health Econ. 2015;24(11):1403–21.CrossRefPubMedGoogle Scholar
  2. 2.
    Asiseh F, Yao J. Family income and body mass index—what have we learned from China. Heal Econ Rev. 2016;6(1):52.CrossRefGoogle Scholar
  3. 3.
    Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin. 2013;7(4):304–83.Google Scholar
  4. 4.
    Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Jung Y. Role of endoscopic gastroplasty techniques in the management of obesity. Clin Endosc. 2017;50(1):21–5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002–13.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Varban OA, Cassidy RB, Bonham A, et al. Factors associated with achieving a body mass index of less than 30 after bariatric surgery. JAMA Surg JAMA Surg. 2017;
  8. 8.
    Chang SH, Stoll CR, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149:275–87.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Allen JW. Laparoscopic gastric band complications. Med Clin N Am. 2007;91:485–97.CrossRefPubMedGoogle Scholar
  10. 10.
    Abu Dayyeh BK, Edmundowicz S, Thompson CC. Clinical practice update: expert review on endoscopic bariatric therapies. Gastroenterology. 2017;152(4):716–29.CrossRefPubMedGoogle Scholar
  11. 11.
    Neylan CJ, Dempsey DT, Tewksbury CM, et al. Endoscopic treatments of obesity: a comprehensive review. Surg Obes Relat Dis. 2016;12(5):1108–15.CrossRefPubMedGoogle Scholar
  12. 12.
    Koehestanie P, de Jonge C, Berends FJ, et al. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Arepally A, Barnett BP, Montgomery E, et al. Catheter-directed gastric artery chemical embolization for modulation of systemic ghrelin levels in a porcine model: initial experience. Radiology. 2007;244(1):138–43.CrossRefPubMedGoogle Scholar
  14. 14.
    Arepally A, Barnett BP, Patel TH, et al. Catheter-directed gastric artery chemical embolization suppresses systemic ghrelin levels in porcine model. Radiology. 2008;249(1):127–33.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bawudun D, Xing Y, Liu WY, et al. Ghrelin suppression and fat loss after left gastric artery embolization in canine model. Cardiovasc Intervent Radiol. 2012;35(6):1460–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Paxton BE, Alley CL, Crow JH, et al. Histopathologic and immunohistochemical sequelae of bariatric embolization in a porcine model. J Vasc Interv Radiol. 2014;25(3):455–61.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Paxton BE, Kim CY, Alley CL, et al. Bariatric embolization for suppression of the hunger hormone ghrelin in a porcine model. Radiology. 2013;266(2):471–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Kipshidze N, Archvadze A, Bertog S, et al. Endovascular bariatrics: first-inman of left gastric artery embolization for weight loss. JACC Cardiovasc Interv. 2015;8(12):1641–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Syed MI, Morar K, Shaikh A, et al. Gastric artery embolization trial for the lessening of appetite nonsurgically (GET LEAN): six-month preliminary data. J Vasc Interv Radiol. 2016;27(10):1502–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Weiss CR, Akinwande O, Paudel K, et al. Clinical safety of bariatric arterial embolization: preliminary results of the BEAT obesity trial. Radiology. 2017;283(2):598–608.CrossRefPubMedGoogle Scholar
  21. 21.
    Mihalache L, Gherasim A, Niță O, et al. Effects of ghrelin in energy balance and body weight homeostasis. Hormones (Athens). 2016;15(2):186–96.CrossRefGoogle Scholar
  22. 22.
    Esler WP, Rudolph J, Claus TH, et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology. 2007;148(11):5175–85.CrossRefPubMedGoogle Scholar
  23. 23.
    Lu SC, Xu J, Chinookoswong N, et al. An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice. Mol Pharmacol. 2009;75(4):901–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Andrade S, Pinho F, Ribeiro AM, et al. Immunization against active ghrelin using virus-like particles for obesity treatment. Curr Pharm Des. 2013;19(36):6551–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Morais T, Andrade S, Pereira SS, et al. Vaccines for metabolic diseases: current perspectives. Vaccine (Auckl). 2014;4:55–72.Google Scholar
  26. 26.
    Prochaska JM, Flye MW, Johnsrude IS. Left gastric artery embolization for control of gastric bleeding: a complication. Radiology. 1973;107:521–2.CrossRefPubMedGoogle Scholar
  27. 27.
    Gunn AJ, OkluR. A preliminary observation of weight loss following left gastric artery embolization in humans. J Obes. 2014;2014:185349.Google Scholar
  28. 28.
    Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.Google Scholar
  29. 29.
    Kangas S, Timonen P, Knuuttila M, et al. Waist circumference and waist-to-height ratio are associated with periodontal pocketing—results of the Health 2000 Survey. BMC Oral Health. 2017;17(1):48.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Levitt MR, Morton RP, Haynor DR, et al. Angiographic perfusion imaging: real-time assessment of endovascular treatment for cerebral vasospasm. J Neuroimaging. 2014;24:387–92.CrossRefPubMedGoogle Scholar
  31. 31.
    Meeks MDME, Mayer J, Desgranges P, et al. Evaluation of infrapopliteal blood flow changes during endovascular revascularization using 2D X-ray perfusion software: a pilot study. Poster presented at CIRSE 2014, Glasgow, UK. Abstract nr 296.Google Scholar
  32. 32.
    Ravussin Y, Leibel RL, Ferrante Jr AW. A missing link in body weight homeostasis: the catabolic signal of the over fed state. Cell Metab. 2014;20(4):565–72.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Hursting SD. Obesity, energy balance, and cancer: a mechanistic perspective. Cancer Treat Res. 2014;159:21–33.CrossRefPubMedGoogle Scholar
  34. 34.
    Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93:S57–63.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Moller JB, Pedersen M, Tanaka H, et al. Body composition is the main determinant for thedifference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care. 2014;37(3):796–804.CrossRefPubMedGoogle Scholar
  36. 36.
    Hwang YC, Hayashi T, Fujimoto Y, et al. Visceral abdominal fat accumulation predicts the conversion of metabolically healthy obese subjects to an unhealthy phenotype. Int J Obes. 2015;39(9):1365–70.CrossRefGoogle Scholar
  37. 37.
    Fischer K, Pick JA, Moewes D, et al. Qualitative aspects of diet affecting visceral and subcutaneous abdominal adipose tissue: a systematic review of observational and controlled intervention studies. Nutr Rev. 2015;73(4):191–215.CrossRefPubMedGoogle Scholar
  38. 38.
    Baum T, Cordes C, Dieckmeyer M, et al. MR-based assessment of body fat distribution and characteristics. Eur J Radiol. 2016;85(8):1512–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Matsuzawa Y, Shimomura I, Nakamura T, et al. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res. 1995; Suppl 2:187S–194S.Google Scholar
  40. 40.
    Fujimoto WY, Abbate SL, Kahn SE, et al. The visceral adiposity syndrome in Japanese-American men. Obes Res. 1994;2(4):364–71.CrossRefPubMedGoogle Scholar
  41. 41.
    Banerji MA, Faridi N, Atluri R, et al. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999;84:137–44.PubMedGoogle Scholar
  42. 42.
    Galanakis CG, Daskalakis M, Manios A, et al. Computed tomography-based assessment of abdominal adiposity changes and their impact on metabolic alterations following bariatric surgery. World J Surg. 2014;39:417–23.CrossRefGoogle Scholar
  43. 43.
    Toro-Ramos T, Goodpaster BH, Janumala I, et al. Continued loss in visceral and intermuscular adipose tissue in weight-stable women following bariatric surgery. Obesity. 2015;23:62–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Kim MK, Kim W, Kwon HS, et al. Effects of bariatric surgery on metabolic and nutritional parameters in severely obese Korean patients with type 2 diabetes: a prospective 2-year follow up. J Diabetes Investig. 2014;5:221–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Yoon DY, Kim HK, Kim JA, et al. Changes in the abdominal fat distribution after gastrectomy: computed tomography assessment. ANZ J Surg. 2007;77:121–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhong-Da Hospital, Medical SchoolSoutheast UniversityNanjingChina

Personalised recommendations